Stephen H. Kawai

2100 Cunard Street
Laval, H7S2G5, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

Journal: ACS medicinal chemistry letters

Published: May 11, 2016

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.

Discovery of BI 207524, an indole diamide NS5B thumb pocket 1 inhibitor with improved potency for the potential treatment of chronic hepatitis C virus infection.

Journal: Journal of medicinal chemistry

Published: November 14, 2014

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor.

Journal: Antimicrobial agents and chemotherapy

Published: March 26, 2014

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV.

Journal: ACS medicinal chemistry letters

Published: March 15, 2014

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Journal: ACS medicinal chemistry letters

Published: January 03, 2014

Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease.

Ligand bioactive conformation plays a critical role in the design of drugs that target the hepatitis C virus NS3 protease.

Journal: Journal of medicinal chemistry

Published: October 23, 2013

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

Journal: Bioorganic & medicinal chemistry letters

Published: February 08, 2013

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

Journal: Bioorganic & medicinal chemistry letters

Published: February 08, 2013

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

Journal: Bioorganic & medicinal chemistry letters

Published: August 27, 2012

Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.

Distinct effects of two HIV-1 capsid assembly inhibitor families that bind the same site within the N-terminal domain of the viral CA protein.

Journal: Journal of virology

Published: April 13, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026